Luyao Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Luyao Li has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Hao Tang
Zhejiang Provincial Key Laboratory of Anti‐Cancer Chinese Medicines and Natural Medicines School of Pharmacy Hangzhou Normal University Hangzhou Zhejiang China
2 shared publicationsLingyu She
School of Pharmacy Hangzhou Medical College Hangzhou Zhejiang China
2 shared publicationsQin Yu
Zhejiang Provincial Key Laboratory of Anti‐Cancer Chinese Medicines and Natural Medicines School of Pharmacy Hangzhou Normal University Hangzhou Zhejiang China
2 shared publications- Xiaoqin Fu
The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University
2 shared publications Aleksandr V. Samorodov
Department of Pharmacology Bashkir State Medical University Ufa Russia
1 shared publicationBinglu Shi
Zhejiang Provincial Key Laboratory of Anti‐Cancer Chinese Medicines and Natural Medicines School of Pharmacy Hangzhou Normal University Hangzhou Zhejiang China
1 shared publication
Latest Publications
- Open Access
- 19 August 2026
- Published by Wiley in Advanced Science
Microglial Deubiquitinase OTUD7B Stabilizes STAT3 to Promote Neuroinflammation and Cognitive Decline in Alzheimer's Disease
Neuroinflammation driven by microglial activation is a defining feature of Alzheimer's disease (AD), yet the molecular mechanisms sustaining this proinflammatory state remain unclear. Here, we identify the deubiquitinase OTUD7B as a critical regulator of microglial activation and AD pathology. OTUD7B expression was markedly elevated in microglia from AD mouse models and human patient datasets. Genetic ablation of OTUD7B markedly attenuated microglial activation and cytokine release, alleviated neuronal injury, and improved cognitive performance in AD mice. Mechanistically, OTUD7B directly interacted with STAT3 and removed K48‐linked ubiquitin chains at lysine 283, thereby stabilizing STAT3, promoting its nuclear translocation, and enhancing transcription of proinflammatory mediators. Integrative transcriptomic analysis revealed that OTUD7B deficiency suppressed proinflammatory transcriptional programs in microglia. Together, these findings uncover an OTUD7B‐STAT3 signaling axis that sustains microglial‐driven neuroinflammation and identify OTUD7B as a potential therapeutic target for mitigating neurodegenerative pathology in AD.
- 19 August 2026
- Published by Wiley in Advanced Science
Open AccessMicroglial Deubiquitinase OTUD7B Stabilizes STAT3 to Promote Neuroinflammation and Cognitive Decline in Alzheimer's Disease
Neuroinflammation driven by microglial activation is a defining feature of Alzheimer's disease (AD), yet the molecular mechanisms sustaining this proinflammatory state remain unclear. Here, we identify the deubiquitinase OTUD7B as a critical regulator of microglial activation and AD pathology. OTUD7B expression was markedly elevated in microglia from AD mouse models and human patient datasets. Genetic ablation of OTUD7B markedly attenuated microglial activation and cytokine release, alleviated neuronal injury, and improved cognitive performance in AD mice. Mechanistically, OTUD7B directly interacted with STAT3 and removed K48‐linked ubiquitin chains at lysine 283, thereby stabilizing STAT3, promoting its nuclear translocation, and enhancing transcription of proinflammatory mediators. Integrative transcriptomic analysis revealed that OTUD7B deficiency suppressed proinflammatory transcriptional programs in microglia. Together, these findings uncover an OTUD7B‐STAT3 signaling axis that sustains microglial‐driven neuroinflammation and identify OTUD7B as a potential therapeutic target for mitigating neurodegenerative pathology in AD.
- Open Access
- 27 November 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (1) , 331-348
YOD1 regulates microglial homeostasis by deubiquitinating MYH9 to promote the pathogenesis of Alzheimer's disease
- 27 November 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (1) , 331-348
Open AccessYOD1 regulates microglial homeostasis by deubiquitinating MYH9 to promote the pathogenesis of Alzheimer's disease
- Open Access
- 2 August 2022
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 18 (3) , 568-576
Chlorogenic acid alleviates hypoxic-ischemic brain injury in neonatal mice
JOURNAL/nrgr/04.03/01300535-202303000-00033/figure1/v/2026-05-25T154646Z/r/image-tiff Recent studies have shown that chlorogenic acid (CGA), which is present in coffee, has protective effects on the nervous system. However, its role in neonatal hypoxic-ischemic brain injury remains unclear. In this study, we established a newborn mouse model of hypoxic-ischemic brain injury using a modified Rice-Vannucci method and performed intraperitoneal injection of CGA. We found that CGA intervention effectively reduced the volume of cerebral infarct, alleviated cerebral edema, restored brain tissue structure after injury, and promoted axon growth in injured brain tissue. Moreover, CGA pretreatment alleviated oxygen-glucose deprivation damage of primary neurons and promoted neuron survival. In addition, changes in ferroptosis-related proteins caused by hypoxic-ischemic brain injury were partially reversed by CGA. Furthermore, CGA intervention upregulated the expression of the key ferroptosis factor glutathione peroxidase 4 and its upstream glutamate/cystine antiporter related factors SLC7A11 and SLC3A2. In summary, our findings reveal that CGA alleviates hypoxic-ischemic brain injury in neonatal mice by reducing ferroptosis, providing new ideas for the treatment of neonatal hypoxic-ischemic brain injury.
- 2 August 2022
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 18 (3) , 568-576
Open AccessChlorogenic acid alleviates hypoxic-ischemic brain injury in neonatal mice
JOURNAL/nrgr/04.03/01300535-202303000-00033/figure1/v/2026-05-25T154646Z/r/image-tiff Recent studies have shown that chlorogenic acid (CGA), which is present in coffee, has protective effects on the nervous system. However, its role in neonatal hypoxic-ischemic brain injury remains unclear. In this study, we established a newborn mouse model of hypoxic-ischemic brain injury using a modified Rice-Vannucci method and performed intraperitoneal injection of CGA. We found that CGA intervention effectively reduced the volume of cerebral infarct, alleviated cerebral edema, restored brain tissue structure after injury, and promoted axon growth in injured brain tissue. Moreover, CGA pretreatment alleviated oxygen-glucose deprivation damage of primary neurons and promoted neuron survival. In addition, changes in ferroptosis-related proteins caused by hypoxic-ischemic brain injury were partially reversed by CGA. Furthermore, CGA intervention upregulated the expression of the key ferroptosis factor glutathione peroxidase 4 and its upstream glutamate/cystine antiporter related factors SLC7A11 and SLC3A2. In summary, our findings reveal that CGA alleviates hypoxic-ischemic brain injury in neonatal mice by reducing ferroptosis, providing new ideas for the treatment of neonatal hypoxic-ischemic brain injury.
- Open Access
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 8336070
Simvastatin Inhibits NLRP3 Inflammasome Activation and Ameliorates Lung Injury in Hyperoxia‐Induced Bronchopulmonary Dysplasia via the KLF2‐Mediated Mechanism
Bronchopulmonary dysplasia (BPD) is a chronic lung disease commonly found in premature infants. Excessive inflammation and oxidative stress contribute to BPD occurrence and development. Simvastatin, as an inhibitor of HMG‐CoA reductase, has been reported to have antioxidative and anti‐inflammatory effects. However, its effect and possible mechanisms in hyperoxia‐induced lung injury are rarely reported. In this study, in vivo and in vitro experiments were conducted to investigate whether simvastatin could ameliorate hyperoxia‐induced lung injury and explore its potential mechanism. For the in vivo study, simvastatin could improve alveolar development after hyperoxic lung injury and reduce hyperoxic stress and inflammation. The in vitro study revealed that simvastatin can reduce inflammation in A549 cells after high‐oxygen exposure. Simvastatin suppressed NLRP3 inflammasome activation and played anti‐inflammatory and antioxidant roles by increasing KLF2 (Krüppel‐like factor 2) expression. In vitro experiments also revealed that these effects of simvastatin were partially reversed by KLF2 shRNA, indicating that KLF2 was involved in simvastatin effects. In summary, our findings indicate that simvastatin could downregulate NLRP3 inflammasome activation and attenuate lung injury in hyperoxia‐induced bronchopulmonary dysplasia via KLF2‐mediated mechanism.
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 8336070
Open AccessSimvastatin Inhibits NLRP3 Inflammasome Activation and Ameliorates Lung Injury in Hyperoxia‐Induced Bronchopulmonary Dysplasia via the KLF2‐Mediated Mechanism
Bronchopulmonary dysplasia (BPD) is a chronic lung disease commonly found in premature infants. Excessive inflammation and oxidative stress contribute to BPD occurrence and development. Simvastatin, as an inhibitor of HMG‐CoA reductase, has been reported to have antioxidative and anti‐inflammatory effects. However, its effect and possible mechanisms in hyperoxia‐induced lung injury are rarely reported. In this study, in vivo and in vitro experiments were conducted to investigate whether simvastatin could ameliorate hyperoxia‐induced lung injury and explore its potential mechanism. For the in vivo study, simvastatin could improve alveolar development after hyperoxic lung injury and reduce hyperoxic stress and inflammation. The in vitro study revealed that simvastatin can reduce inflammation in A549 cells after high‐oxygen exposure. Simvastatin suppressed NLRP3 inflammasome activation and played anti‐inflammatory and antioxidant roles by increasing KLF2 (Krüppel‐like factor 2) expression. In vitro experiments also revealed that these effects of simvastatin were partially reversed by KLF2 shRNA, indicating that KLF2 was involved in simvastatin effects. In summary, our findings indicate that simvastatin could downregulate NLRP3 inflammasome activation and attenuate lung injury in hyperoxia‐induced bronchopulmonary dysplasia via KLF2‐mediated mechanism.